Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class trea

Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B

Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal PhIII B-Well trials